Novartis posts better-than-expected sales driven by medicine demand
The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core operating income set to grow by low double-digits.
The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core operating income set to grow by low double-digits.
What's Your Reaction?
